Affordable Access

Interferon-beta increases systemic BAFF levels in multiple sclerosis without increasing autoantibody production

Authors
Publisher
Sage Science Press (UK)
Publication Date
Keywords
  • Background: Treatment With Interferon-Beta (Ifn-Beta) Increases B-Cell Activating Factor Of The Tnf
  • Raising The Concern That Treatment Of Ms Patients With Ifn-Beta May Activate Autoimmune B Cells And
  • Objective: To Investigate Whether Baff Levels Are Associated With Disease Severity/Activity In Untre
  • And To Assess The Effect Of Ifn-Beta Therapy On Circulating Baff And Anti-Myelin Basic Protein (Mbp)
  • Results: Twenty-Three Patients With Relapsing–Remitting Ms (Rrms) Were Followed Longitudinally Fro
  • Their Blood Levels Of Baff Correlated Positively At Baseline With The Expanded Disability Status Sca
  • 0
  • 009) And Ms Severity Score (P &Lt
  • 0
  • 05)
  • But Not With Disease Activity As Determined By The Number Of Gadolinium-Enhanced Lesions
  • The Patients Were Followed For Up To 26 Months
  • During Which The Baff Levels Remained Elevated Without Association To Increased Disease Activity
  • Ifn-Beta Therapy Caused An Increase In Plasma Baff Levels After Both 3 And 6 Months Of Therapy (P &L
  • 0
  • 002)
  • However
  • An 11% Decrease In Igm And A 33% Decrease In Igg Anti-Mbp Autoantibodies (P &Lt
  • 0
  • 09 And P &Lt
  • 0
  • 009
  • Respectively) Was Observed After 6 Months
  • Conclusion: Pre-Treatment Baff Levels Correlate With High Disability Scores In Ms
  • Suggesting That High Baff Expression Is A Negative Prognostic Marker
  • Despite Its Known Beneficial Effects
  • Ifn-Beta Therapy Causes A Sustained Increase In Plasma Baff Levels
  • Which Does Not Translate Into Increased Levels Of Anti-Mbp Autoantibodies

Abstract

Interferon-beta increases systemic BAFF levels in multiple sclerosis without increasing autoantibody production - DTU Orbit (22/04/14) Interferon-beta increases systemic BAFF levels in multiple sclerosis without increasing autoantibody production - DTU Orbit (22/04/14) Hedegaard CJ, Sellebjerg F, Krakauer M, Hesse D, Bendtzen K, Nielsen CH. 2011. Interferon-beta increases systemic BAFF levels in multiple sclerosis without increasing autoantibody production. Multiple Sclerosis. 17(5):567-577. Available from: 10.1177/1352458510393771

There are no comments yet on this publication. Be the first to share your thoughts.